Chlamydia protein, gene sequence and uses thereof

Details Chlamydia protein, gene sequence and uses thereof Chlamydia protein, gene sequence and uses thereof

2004-09-01

2010-02-02

Mondesi, Robert B (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S190100, C530S350000, C536S023100, C536S023700, C435S069100, C435S069700

Reexamination Certificate

active

07655246

ABSTRACT:
A high molecular weight (“HMW”) protein ofChlamydia, the amino acid sequence thereof, and antibodies that specifically bind the HMW protein are disclosed as well as the nucleic acid sequence encoding the same. Also disclosed are prophylactic and therapeutic compositions, comprising the HMW protein, a fragment thereof, or an antibody that specifically binds the HMW protein or a portion thereof, or the nucleotide sequence encoding the HMW protein or a fragment thereof, including vaccines.

REFERENCES:
patent: 4427782 (1984-01-01), Caldwell et al.
patent: 4855283 (1989-08-01), Lockhoff et al.
patent: 4935352 (1990-06-01), Igarashi et al.
patent: 5071962 (1991-12-01), Morrison et al.
patent: 5516638 (1996-05-01), Urnovitz et al.
patent: 5565352 (1996-10-01), Hochstrasser et al.
patent: 5629167 (1997-05-01), Ratti
patent: 5725863 (1998-03-01), Daniels et al.
patent: 5750110 (1998-05-01), Prieels et al.
patent: 5807978 (1998-09-01), Kokolus et al.
patent: 5849306 (1998-12-01), Sim et al.
patent: 5871977 (1999-02-01), Kubota et al.
patent: 5965141 (1999-10-01), Briles et al.
patent: 5976544 (1999-11-01), Charles et al.
patent: 6019982 (2000-02-01), Clements et al.
patent: 6077693 (2000-06-01), Tang et al.
patent: 6565856 (2003-05-01), Skeiky et al.
patent: 6642023 (2003-11-01), Jackson et al.
patent: 6887843 (2005-05-01), Jackson et al.
patent: 2004/0037846 (2004-02-01), Jackson
patent: 2004/0067524 (2004-04-01), Jackson et al.
patent: 2004/0137005 (2004-07-01), Jackson et al.
patent: 2005/0281847 (2005-12-01), Berthet et al.
patent: 0 818 681 (1998-01-01), None
patent: WO 94/01548 (1994-01-01), None
patent: WO 95/12411 (1995-05-01), None
patent: WO 96/31236 (1996-10-01), None
patent: WO 98/10789 (1998-03-01), None
patent: WO 99/17741 (1999-04-01), None
patent: WO 99/28475 (1999-06-01), None
patent: WO 99/31236 (1999-06-01), None
patent: WO 00/34483 (2000-06-01), None
patent: WO 01/40474 (2001-06-01), None
patent: WO 02/08267 (2002-01-01), None
patent: WO 2008/156729 (2008-12-01), None
Unanue, ER 1999, American Journal of Pathology; 154; 651-664.
Lederman et al (Molecular Immunology 28:1171-1181, 1991.
Li et al (Proc. Natl. Acad. Sci. USA 77:3211-3214, 1980.
Greenspan et al (Nature Biotechnology, 1999, 7:936-937).
Holmes, Exp. Opin.Invest. Drugs, 2001, 10(3):511-519.
Birkelund et al., Infection & Immunity, 56(3):654-59, Mar. 1988.
Buenida et al., FEMS Microbiol. Lttrs., May 1, 150(1):113-119 (1997).
Caldwell, et al., Infec. Immun., 31(3):1161-1176 (1981).
Cerrone et al., Infec. Immun., 59(1):79-90 (1991).
Chen et al., Molecular Microbiology 11(3):501-507 (1994).
Li et al., PNAS 77(6):3211-14 (1980).
DeSa et al., Infection & immunity, Dec., 63(12):4912-16 (1995).
Murdin et al., Infec. Immun., 63(3):1116-1121 (1995).
Murdin et al., Infec. Immun., 61(10):4406-4414 (1993).
Sexton et al., J. of Immunol., 152(4):1861-72 (1994).
Su et al., PNAS 93:11143-48 (1986).
Swanson et al., Infec. Immun., 38(2):502-507 (1990).
Wager et al., Infec. Immun., 56(7):1678-1684 (1988).
Zhang et al., Cell, 69:861-869 (1992).
Herring et al., FEMS Microbiol Letts., 65:153-158 (1989).
Tan et al., Infect. Immun., 58(9):3101-3108 (1990).
Zhang et al., Nucleic Acids Res., 18(4):1061 (1990).
Stephens et al., J. Bacteriol, 168:1277-82 (1986).
Pal et al., Infection & Immunity, 65:3361-3369, Aug. 1997.
Christiansen et al., Scand J Infect Dis Suppl, 104:5-10 (1997).
Sandbulte et al., Veterinary Microbiology, 48:269-282 (1996).
Amersdorfer, P., et al., “Molecular Characterization of Murine Humoral Immune Response to Botulinum Neurotoxin Type A Binding Domain as Assessed by Using Phage Antibody Libraries,”Infect. Immun. 65:3743-3752, American Society For Microbiology (Sep. 1997).
Barenkamp, S.J., and St. Geme III, J.W., “Identification of Surface-Exposed B-Cell Epitopes on High-Molecular-Weight Adhesion Proteins of NontypeableHaemophilus influenzae,” Infect. Immun. 64:3032-3037, American Society For Microbiology (Aug. 1996).
Batteiger, B.E., et al., “Species-, Serogroup-, and Serovar-Specific Epitopes Are Juxtaposed in Variable Sequence Region 4 of the Major Outer Membrane Proteins of SomeChlamydia trachomatisSerovars,”Infect. Immun. 64:2839-2841, American Society For Microbiology (Jul. 1996).
Baughn, R.E., et al., “Epitope Mapping of B-Cell Determinants on the 15-Kilodalton Lipoprotein ofTreponema pallidum(Tpp15) with Synthetic Peptides,”Infect. Immun. 64:2457-2466, American Society For Microbiology (Jul. 1996).
Brown, D.R., et al., “Identification and Characterization of a Neutralizing Monoclonal Antibody Against Botulinum Neurotoxin, Serotype F, Following Vaccination With Active Toxin,”Hybridoma16:447-456, Mary Ann Leibert, Inc, (Oct. 1997).
Burnie, J.P., et al., “Defining Antibody Targets inStreptococcus oralisInfection,”Infect. Immun. 64:1600-1608, American Society For Microbiology (May 1996).
Cunningham, M.W., et al., “Molecular Analysis of Human Cardiac Myosin-Cross-Reactive B- and T-Cell Epitopes of the Group AStreptococcalM5 Protein,”Infect. Immun. 65:3913-3923, American Society For Microbiology (Sep. 1997).
Davies, D.R., and Cohen, G.H., “Interactions of protein antigens with antibodies,”Proc. Natl. Acad. Sci. USA 93:7-12, National Academy of Sciences (Jan. 1996).
De Sa, C., “La proéine majeure de la membrane externe deChlamydia: structure et fonctions,”Vet. Res. 27:317-331, ZDP Sciences (Feb. 1996).
Delvig, A.A., et al., “Immune responses to linear epitopes on the PorB protein ofNeisseria meningitidisin patients with systemic meningococcal disease,”Microbiology 142:2491-2498, Society for General Microbiology (Sep. 1996).
Deslauriers, M., et al., “Identification of Murine Protective Epitopes on thePorphyromonas gingivalisFimbrillin Molecule,”Infect. Immun. 64:434-440, American Society for Microbiology (Feb. 1996).
Duim, B., et al., “Fine Mapping of Outer Membrane Protein P2 Antigenic Sites Which Vary During Persistent Infection byHaemophilus influenzae,” Infect. Immun. 64:4673-4679, American Society For Microbiology (Nov. 1996).
Fan, J., and Stephens, R.S., “Antigen Conformation Dependence ofChlamydia trachomatisInfectivity Neutralization,”J. Infect. Dis. 176:713-721, University of Chicago Press (Sep. 1997).
Ghadjari, A., et al., “Epitope mappingCandida albicansproteinase (SAP 2),”FEMS Immunol. Med. Microbiol. 19:115-123, Elsevier Science (Oct. 1997).
Goodman, J.W., “Immunogenicity & Antigenic Specificity,” inBasic and Clinical Immunol., Stites, D.P., et al., eds., Appleton & Lange, Norwalk, CT, pp. 101-108 (1991).
Janeway, C., et al.,Immunogenicity, John Wiley & Sons, Inc., New York, NY, pp. 65-71 (1989).
Ji, Y., et al., “Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group AStreptococcus,” Infect. Immun. 65:2080-2087, American Society for Microbiology (Jun. 1997).
Lainson, F.A., et al., “Characterization of epitopes involved in the neutralization ofPasteurella haemolyticaserotype A1 leukotoxin,”Microbiology 142:2499-2507, Society for General Microbiology (Sep. 1996).
Méchin, M., et al., “Identification of Surface-Exposed Linear B-Cell Epitopes of the Nonfimbrial Adhesin CS31A ofEscherichia coliby Using Overlapping Peptides and Antipeptide Antibodies,”Infect. Immun. 64:3555-3564, American Society for Microbiology (Sep. 1996).
Morris, G.E.,Methods in Molecular Biology, vol. 66:Epitope Mapping, Morris, G.E., ed., Humana Press, Totowa, NJ (1996).
Oettinger, T., et al., “Characterization of the Delayed Type Hypersensitivity-Inducing Epitope of MPT64 fromMycobacterium tuberculosis,” Scand. J. Immunol. 45:499-503, Blackwell Science, Ltd. (May 1997).
Pal, S., et al., “Monoclonal immunoglobulin A antibody to the major outer membrane protein ofChlamydia trachomatismouse pneumonitis biovar protects mice against a genital chlamydial challenge,”Vac

Affiliated with

Also associated with

Rating

Chlamydia protein, gene sequence and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chlamydia protein, gene sequence and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chlamydia protein, gene sequence and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4151270